Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis

European Journal of Immunology

Volumn 46, Issue 9, 2016, Pages 2078-2090

  Martin, Roland ^a   Sospedra, Mireia ^a   Rosito, Maria ^b   Engelhardt, Britta ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Autoantibodies; Autoimmune pathogenesis; Autoimmunity; Autoreactive B cells; Autoreactive T cells; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Treatment

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; RITUXIMAB; TERIFLUNOMIDE;

ANTIGEN PRESENTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BLOOD BRAIN BARRIER; CLINICAL PRACTICE; DISEASE ACTIVITY; DRUG MECHANISM; GENETIC VARIABILITY; GLIA CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW;

EID: 84985946870     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201646485     Document Type: Review

References (129)

1. Sospedra, M. and Martin, R., Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005. 23: 683–747.
2. Ciccarelli, O., Barkhof, F., Bodini, B., De Stefano, N., Golay, X., Nicolay, K., Pelletier, D. et al., Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. Lancet Neurol. 2014. 13: 807–822.
3. Noseworthy, J. H., Lucchinetti, C., Rodriguez, M. and Weinshenker, B. G., Multiple sclerosis. N. Engl. J. Med. 2000. 343: 938–952.
4. Steinman, L. and Zamvil, S. S., How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 2006. 60: 12–21.
5. Martin, R., McFarland, H. F. and McFarlin, D. E., Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 1992. 10: 153–187.
6. Krishnamoorthy, G. and Wekerle, H., EAE: an immunologist's magic eye. Eur. J. Immunol. 2009. 39: 2031–2035.
7. Lassmann, H. and van Horssen, J., The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett. 2011. 585: 3715–3723.
8. Yshii, L., Gebauer, C., Bernard-Valnet, R. and Liblau, R., Neurons and T cells: understanding this interaction for inflammatory neurological diseases. Eur. J. Immunol. 2015. 45: 2712–2720.
9. Hoffmann, F. and Meinl, E., B cells in multiple sclerosis: good or bad guys? An article for 28 May 2014—World MS Day 2014. Eur. J. Immunol. 2014. 44: 1247–1250.
10. Cao, Y., Goods, B. A., Raddassi, K., Nepom, G. T., Kwok, W. W., Love, J. C. and Hafler, D. A., Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis. Sci. Transl. Med. 2015. 7: 287ra274.
11. Hartmann, F. J., Khademi, M., Aram, J., Ammann, S., Kockum, I., Constantinescu, C., Gran, B. et al., Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells. Nat. Commun. 2014. 5: 5056.
12. Planas, R., Metz, I., Ortiz, Y., Vilarrasa, N., Jelcic, I., Salinas-Riester, G., Heesen, C. et al., Central role of Th2/Tc2 lymphocytes in pattern II multiple sclerosis lesions. Ann. Clin. Transl. Neurol. 2015. 2: 875–893.
13. Lucchinetti, C., Bruck, W., Parisi, J., Scheithauer, B., Rodriguez, M. and Lassmann, H., Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000. 47: 707–717.
14. Madsen, L. S., Andersson, E. C., Jansson, L., Krogsgaard, M., Andersen, C. B., Engberg, J., Strominger, J. L. et al., A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat. Genet. 1999. 23: 343–347.
15. Quandt, J. A., Baig, M., Yao, K., Kawamura, K., Huh, J., Ludwin, S. K., Bian, H. J. et al., Unique clinical and pathological features in HLA-DRB1*0401-restricted MBP 111-129-specific humanized TCR transgenic mice. J. Exp. Med. 2004. 200: 223–234.
16. Quandt, J. A., Huh, J., Baig, M., Yao, K., Ito, N., Bryant, M., Kawamura, K. et al., Myelin basic protein-specific TCR/HLA-DRB5*01:01 transgenic mice support the etiologic role of DRB5*01:01 in multiple sclerosis. J. Immunol. 2012. 189: 2897–2908.
17. Bielekova, B., Goodwin, B., Richert, N., Cortese, I., Kondo, T., Afshar, G., Gran, B. et al., Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 2000. 6: 1167–1175.
18. Jersild, C., Svejgaard, A. and Fog, T., HL-A antigens and multiple sclerosis. Lancet 1972. 1: 1240–1241.
19. International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium, Sawcer, S., Hellenthal, G., Pirinen, M., Spencer, C. C., Patsopoulos, N. A.et al., Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011. 476: 214–219.
20. International Multiple Sclerosis Genetics Consortium, Beecham, A. H., Patsopoulos, N. A., Xifara, D. K., Davis, M. F., Kemppinen, A., Cotsapas, C. et al., Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013. 45: 1353–1360.
21. Babbe, H., Roers, A., Waisman, A., Lassmann, H., Goebels, N., Hohlfeld, R., Friese, M. et al., Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 2000. 192: 393–404.
22. Huseby, E. S., Liggitt, D., Brabb, T., Schnabel, B., Ohlen, C. and Goverman, J., A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J. Exp. Med. 2001. 194: 669–676.
23. Suzumura, A., Silberberg, D. H. and Lisak, R. P., The expression of MHC antigens on oligodendrocytes: induction of polymorphic H-2 expression by lymphokines. J. Neuroimmunol. 1986. 11: 179–190.
24. Neumann, H., Cavalie, A., Jenne, D. E. and Wekerle, H., Induction of MHC class I genes in neurons. Science 1995. 269: 549–552.
25. Elliott, C., Lindner, M., Arthur, A., Brennan, K., Jarius, S., Hussey, J., Chan, A. et al., Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain 2012. 135: 1819–1833.
26. Flach, A. C., Litke, T., Strauss, J., Haberl, M., Gomez, C. C., Reindl, M., Saiz, A. et al., Autoantibody-boosted T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease. Proc. Natl. Acad. Sci. USA 2016. 113: 3323–3328.
27. Mathey, E. K., Derfuss, T., Storch, M. K., Williams, K. R., Hales, K., Woolley, D. R., Al-Hayani, A. et al., Neurofascin as a novel target for autoantibody-mediated axonal injury. J. Exp. Med. 2007. 204: 2363–2372.
28. Derfuss, T., Parikh, K., Velhin, S., Braun, M., Mathey, E., Krumbholz, M., Kumpfel, T. et al., Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc. Natl. Acad. Sci. USA 2009. 106: 8302–8307.
29. Srivastava, R., Aslam, M., Kalluri, S. R., Schirmer, L., Buck, D., Tackenberg, B., Rothhammer, V. et al., Potassium channel KIR4.1 as an immune target in multiple sclerosis. N. Engl. J. Med. 2012. 367: 115–123.
30. Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A. et al., B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008. 358: 676–688.
31. Li, R., Rezk, A., Miyazaki, Y., Hilgenberg, E., Touil, H., Shen, P., Moore, C. S. et al., Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci. Transl. Med. 2015. 7: 310ra166.
32. Frischer, J. M., Weigand, S. D., Guo, Y., Kale, N., Parisi, J. E., Pirko, I., Mandrekar, J. et al., Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann. Neurol. 2015. 78: 710–721.
33. Miller, D. H., Khan, O. A., Sheremata, W. A., Blumhardt, L. D., Rice, G. P., Libonati, M. A., Willmer-Hulme, A. J. et al., A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2003. 348: 15–23.
34. Coles, A. J., Fox, E., Vladic, A., Gazda, S. K., Brinar, V., Selmaj, K. W., Bass, A. D. et al., Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011. 10: 338–348.
35. Kappos, L., Wiendl, H., Selmaj, K., Arnold, D. L., Havrdova, E., Boyko, A., Kaufman, M. et al., Daclizumab HYP versus interferon Beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 2015. 373: 1418–1428.
36. Straus Farber, R., Harel, A. and Lublin, F., Novel agents for relapsing forms of multiple sclerosis. Annu. Rev. Med. 2016. 67: 309–321.
37. Jacobs, L., O'Malley, J., Freeman, A., Murawski, J. and Ekes, R., Intrathecal interferon in multiple sclerosis. Arch. Neurol. 1982. 39: 609–615.
38. Paty, D. W. and Li, D. K., Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993. 43: 662–667.
39. Leppert, D., Waubant, E., Burk, M. R., Oksenberg, J. R. and Hauser, S. L., Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 1996. 40: 846–852.
40. Stuve, O., Dooley, N. P., Uhm, J. H., Antel, J. P., Francis, G. S., Williams, G. and Yong, V. W., Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 1996. 40: 853–863.
41. Uhm, J. H., Dooley, N. P., Stuve, O., Francis, G. S., Duquette, P., Antel, J. P. and Yong, V. W., Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon beta-1b therapy. Ann. Neurol. 1999. 46: 319–324.
42. Jiang, H., Milo, R., Swoveland, P., Johnson, K. P., Panitch, H. and Dhib-Jalbut, S., Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells. J. Neuroimmunol. 1995. 61: 17–25.
43. Kozovska, M. E., Hong, J., Zang, Y. C., Li, S., Rivera, V. M., Killian, J. M. and Zhang, J. Z., Interferon beta induces T-helper 2 immune deviation in MS. Neurology 1999. 53:1692–1697.
44. Dhib-Jalbut, S. and Marks, S., Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010. 74 1: S17–S24.
45. Ristori, G., Montesperelli, C., Gasperini, C., Battistini, L., Borsellino, G., Buttinelli, C., Cannoni, S. et al., T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosis. J. Neuroimmunol. 1999. 99: 91–96.
46. Teitelbaum, D., Webb, C., Bree, M., Meshorer, A., Arnon, R. and Sela, M., Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer. Clin. Immunol. Immunopathol. 1974. 3: 256–262.
47. Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W. et al., Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial, 1995. Neurology 2001. 57: S16–S24.
48. Racke, M. K., Martin, R., McFarland, H. and Fritz, R. B., Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation. J. Neuroimmunol. 1992. 37: 75–84.
49. Aharoni, R., Teitelbaum, D., Sela, M. and Arnon, R., Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 1997. 94: 10821–10826.
50. Zang, Y., Hong, J., Robinson, R., Li, S., Rivera, V. M. and Zhang, J. Z., Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis. J. Neuroimmunol. 2003. 137: 144–153.
51. Karandikar, N. J., Crawford, M. P., Yan, X., Ratts, R. B., Brenchley, J. M., Ambrozak, D. R., Lovett-Racke, A. E. et al., Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J. Clin. Invest. 2002. 109: 641–649.
52. Weber, M. S., Prod'homme, T., Youssef, S., Dunn, S. E., Rundle, C. D., Lee, L., Patarroyo, J. C. et al., Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med. 2007. 13: 935–943.
53. Gran, B., Tranquill, L. R., Chen, M., Bielekova, B., Zhou, W., Dhib-Jalbut, S. and Martin, R., Mechanisms of immunomodulation by glatiramer acetate. Neurology 2000. 55: 1704–1714.
54. Dhib-Jalbut, S., Chen, M., Said, A., Zhan, M., Johnson, K. P. and Martin, R., Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype. J. Neuroimmunol. 2003. 140: 163–171.
55. Ziemssen, T., Kumpfel, T., Schneider, H., Klinkert, W. E., Neuhaus, O. and Hohlfeld, R., Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: implications for multiple sclerosis therapy. J. Neurol. Sci. 2005. 233: 109–112.
56. Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L. and Karin, N., Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992. 356: 63–66.
57. Engelhardt, B., Laschinger, M., Schulz, M., Samulowitz, U., Vestweber, D. and Hoch, G., The development of experimental autoimmune encephalomyelitis in the mouse requires alpha4-integrin but not alpha4beta7-integrin. J. Clin. Invest. 1998. 102: 2096–2105.
58. Baldwin, K. J. and Hogg, J. P., Progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Curr. Opin. Neurol. 2013. 26: 318–323.
59. Major, E. O., Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu. Rev. Med. 2010. 61: 35–47.
60. Aly, L., Yousef, S., Schippling, S., Jelcic, I., Breiden, P., Matschke, J., Schulz, R. et al., Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain 2011. 134: 2687–2702.
61. Planas, R., Jelcic, I., Schippling, S., Martin, R. and Sospedra, M., Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur. J. Immunol. 2012. 42: 790–798.
62. Jelcic, I., Jelcic, I., Kempf, C., Largey, F., Planas, R., Schippling, S., Budka, H. et al., Mechanisms of immune escape in central nervous system infection with neurotropic JC virus variant. Ann. Neurol. 2016. 79: 404–418.
63. Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S. et al., Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug. Discov. 2010. 9: 883–897.
64. Blaho, V. A. and Hla, T., An update on the biology of sphingosine 1-phosphate receptors. J. Lipid Res. 2014. 55: 1596–1608.
65. Suzuki, S., Enosawa, S., Kakefuda, T., Shinomiya, T., Amari, M., Naoe, S., Hoshino, Y. et al., A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 1996. 61: 200–205.
66. Fujino, M., Funeshima, N., Kitazawa, Y., Kimura, H., Amemiya, H., Suzuki, S. and Li, X. K., Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. 2003. 305: 70–77.
67. Kappos, L., Radue, E. W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K. et al., A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010. 362: 387–401.
68. Yanagawa, Y., Masubuchi, Y. and Chiba, K., FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing. Immunology 1998. 95: 591–594.
69. Ricklin, M. E., Lorscheider, J., Waschbisch, A., Paroz, C., Mehta, S. K., Pierson, D. L., Kuhle, J. et al., T-cell response against varicella-zoster virus in fingolimod-treated MS patients. Neurology 2013. 81: 174–181.
70. Pfender, N., Jelcic, I., Linnebank, M., Schwarz, U. and Martin, R., Reactivation of herpesvirus under fingolimod: a case of severe herpes simplex encephalitis. Neurology 2015. 84: 2377–2378.
71. Gyang, T. V., Hamel, J., Goodman, A. D., Gross, R. A. and Samkoff, L., Fingolimod-associated PML in a patient with prior immunosuppression. Neurology 2016. 86: 1843–1845.
72. Rozman, B., Clinical pharmacokinetics of leflunomide. Clin. Pharmacokinet. 2002. 41: 421–430.
73. O'Connor, P. W., Li, D., Freedman, M. S., Bar-Or, A., Rice, G. P., Confavreux, C., Paty, D. W. et al., A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006. 66: 894–900.
74. O'Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Benzerdjeb, H. et al., Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 2011. 365: 1293–1303.
75. Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C. et al., Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 2012. 367: 1098–1107.
76. Bar-Or, A., Pachner, A., Menguy-Vacheron, F., Kaplan, J. and Wiendl, H., Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 2014. 74: 659–674.
77. Dubiel, W. and Happle, R., Experimental treatment with fumaric acid monoethylester in psoriasis vulgaris. Z. Haut Geschlechtskr. 1972. 47: 545–550.
78. Ghoreschi, K., Bruck, J., Kellerer, C., Deng, C., Peng, H., Rothfuss, O., Hussain, R. Z. et al., Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J. Exp. Med. 2011. 208: 2291–2303.
79. Linker, R. A., Lee, D. H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W. et al., Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011. 134: 678–692.
80. Lundy, S. K., Wu, Q., Wang, Q., Dowling, C. A., Taitano, S. H., Mao, G. and Mao-Draayer, Y., Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets. Neurol. Neuroimmunol. Neuroinflamm. 2016. 3: e211.
81. Rosenkranz, T., Novas, M. and Terborg, C., PML in a patient with lymphocytopenia treated with dimethyl fumarate. N. Engl. J. Med. 2015. 372: 1476–1478.
82. Heit, W., Bunjes, D., Wiesneth, M., Schmeiser, T., Arnold, R., Hale, G., Waldmann, H. et al., Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation. Br. J. Haematol. 1986. 64: 479–486.
83. Osterborg, A., Fassas, A. S., Anagnostopoulos, A., Dyer, M. J., Catovsky, D. and Mellstedt, H., Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br. J. Haematol. 1996. 93: 151–153.
84. Coles, A., Deans, J. and Compston, A., Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin. Neurol. Neurosurg. 2004. 106: 270–274.
85. Cox, A. L., Thompson, S. A., Jones, J. L., Robertson, V. H., Hale, G., Waldmann, H., Compston, D. A. et al., Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 2005. 35: 3332–3342.
86. Cossburn, M., Pace, A. A., Jones, J., Ali, R., Ingram, G., Baker, K., Hirst, C. et al., Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011. 77: 573–579.
87. Hauser, S. L., Comi, G. C., Hartung, H.-P., Selmaj, K., Traboulsee, A., Bar-Or, A., Arnold, D. L. et al., Efficacy and safety of ocrelizumab in relapsing multiple sclerosis—results of the interferon-beta-1a-controlled, double-blind, Phase III OPERA I and II studies. ECTRIMS 2015. 116701; abstract: 190.
88. Sorensen, P. S., Lisby, S., Grove, R., Derosier, F., Shackelford, S., Havrdova, E., Drulovic, J. et al., Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology 2014. 82: 573–581.
89. Hawker, K., O'Connor, P., Freedman, M. S., Calabresi, P. A., Antel, J., Simon, J., Hauser, S. et al., Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 2009. 66: 460–471.
90. Montalban, X., Hemmer, B., Rammohan, K., Giovannoni, G., de Seze, J., Bar-Or, A., Arnold, D. L. et al., Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis—results of the placebo-controlled, double-blind, Phase III ORATORIO study. ECTRIMS 2015. 116701; abstract: 228.
91. Serafini, B., Rosicarelli, B., Franciotta, D., Magliozzi, R., Reynolds, R., Cinque, P., Andreoni, L. et al., Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 2007. 204: 2899–2912.
92. Lucchinetti, C. F., Popescu, B. F., Bunyan, R. F., Moll, N. M., Roemer, S. F., Lassmann, H., Bruck, W. et al., Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 2011. 365: 2188–2197.
93. Vincenti, F., Kirkman, R., Light, S., Bumgardner, G., Pescovitz, M., Halloran, P., Neylan, J. et al., Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N. Engl. J. Med. 1998. 338: 161–165.
94. Waldmann, T. A., The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol. Today 1993. 14: 264–270.
95. Nussenblatt, R. B., Fortin, E., Schiffman, R., Rizzo, L., Smith, J., Van Veldhuisen, P., Sran, P. et al., Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc. Natl. Acad. Sci. USA 1999. 96: 7462–7466.
96. Bielekova, B., Richert, N., Howard, T., Blevins, G., Markovic-Plese, S., McCartin, J., Frank, J. A. et al., Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc. Natl. Acad. Sci. USA 2004. 101: 8705–8708.
97. Bielekova, B., Catalfamo, M., Reichert-Scrivner, S., Packer, A., Cerna, M., Waldmann, T. A., McFarland, H. et al., Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. USA 2006. 103: 5941–5946.
98. Wuest, S. C., Edwan, J. H., Martin, J. F., Han, S., Perry, J. S., Cartagena, C. M., Matsuura, E. et al., A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat. Med. 2011. 17: 604–609.
99. Perry, J. S., Han, S., Xu, Q., Herman, M. L., Kennedy, L. B., Csako, G. and Bielekova, B., Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci. Transl. Med. 2012. 4: 145ra106.
100. Gross, C. C., Schulte-Mecklenbeck, A., Runzi, A., Kuhlmann, T., Posevitz-Fejfar, A., Schwab, N., Schneider-Hohendorf, T. et al., Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proc. Natl. Acad. Sci. USA 2016. 113: E2973–E2982.
101. Tokuda, Y., Ohta, M., Okumura, A., Kuge, S., Kubota, M., Tajima, T. and Mitomi, T., High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in breast cancer. Cancer Chemother. Pharmacol. 1997. 40: S94–S99.
102. Mancardi, G. and Saccardi, R., Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol. 2008. 7: 626–636.
103. Mancardi, G. L., Sormani, M. P., Gualandi, F., Saiz, A., Carreras, E., Merelli, E., Donelli, A. et al., Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology 2015. 84: 981–988.
104. Muraro, P. A., Pasquini, M., Atkins, H., Bowen, J., Farge, D., Fassas, A., Freedman, M. S. et al., Long term outcomes after autologous hematopoietic stem cell transplantation for treatment of MS. ECTRIMS 2015. 116682; abstract: 193.
105. Atkins, H. L., Bowman, M., Allan, D., Anstee, G., Arnold, D. L., Bar-Or, A., Bence-Bruckler, I. et al., Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet 2016. 388: 576–585.
106. Muraro, P. A., Douek, D. C., Packer, A., Chung, K., Guenaga, F. J., Cassiani-Ingoni, R., Campbell, C. et al., Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J. Exp. Med. 2005. 201: 805–816.
107. Abrahamsson, S. V., Angelini, D. F., Dubinsky, A. N., Morel, E., Oh, U., Jones, J. L., Carassiti, D. et al., Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain 2013. 136: 2888–2903.
108. Baker, D., Butler, D., Scallon, B. J., O'Neill, J. K., Turk, J. L. and Feldmann, M., Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur. J. Immunol. 1994. 24: 2040–2048.
109. Sharief, M. K. and Hentges, R., Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N. Engl. J. Med. 1991. 325: 467–472.
110. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999. 53: 457–465.
111. Sicotte, N. L. and Voskuhl, R. R., Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001. 57: 1885–1888.
112. Codarri, L., Fontana, A. and Becher, B., Cytokine networks in multiple sclerosis: lost in translation. Curr. Opin. Neurol. 2010. 23: 205–211.
113. Panitch, H. S., Hirsch, R. L., Haley, A. S. and Johnson, K. P., Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987. 1: 893–895.
114. Lin, W., Kemper, A., Dupree, J. L., Harding, H. P., Ron, D. and Popko, B., Interferon-gamma inhibits central nervous system remyelination through a process modulated by endoplasmic reticulum stress. Brain 2006. 129: 1306–1318.
115. Kroenke, M. A., Carlson, T. J., Andjelkovic, A. V. and Segal, B. M., IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 2008. 205: 1535–1541.
116. Segal, B. M., Constantinescu, C. S., Raychaudhuri, A., Kim, L., Fidelus-Gort, R., Kasper, L. H. and Ustekinumab, M. S. I., Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008. 7: 796–804.
117. Croxford, A. L., Mair, F. and Becher, B., IL-23: one cytokine in control of autoimmunity. Eur. J. Immunol. 2012. 42: 2263–2273.
118. Engelhardt, B. and Sorokin, L., The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin. Immunopathol. 2009. 31: 497–511.
119. Ransohoff, R. M. and Engelhardt, B., The anatomical and cellular basis of immune surveillance in the central nervous system. Nat. Rev. Immunol. 2012. 12: 623–635.
120. Owens, T., Bechmann, I. and Engelhardt, B., Perivascular spaces and the two steps to neuroinflammation. J. Neuropathol. Exp. Neurol. 2008. 67: 1113–1121.
121. Ellwardt, E., Walsh, J. T., Kipnis, J. and Zipp, F., Understanding the role of T cells in CNS homeostasis. Trends Immunol. 2016. 37: 154–165.
122. Deczkowska, A., Baruch, K. and Schwartz, M., Type I/II interferon balance in the regulation of brain physiology and pathology. Trends Immunol. 2016. 37: 181–192.
123. Cserr, H.F., Harling-Berg, C. J. and Knopf P.M., Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathology. 1992. 2:269–276.
124. Kida, S., Pantazis, A. and Weller, R. O., CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological significance. Neuropathol. Appl. Neurobiol. 1993. 19:480–488.
125. Johnston, M., Zakharov, A., Papaiconomou, C., Salmasi, G. and Armstrong, D., Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res. 2004. 1: 2–15
126. Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C. et al., Structural and functional features of central nervous system lymphatic vessels. Nature 2015. 523: 337–341.
127. Aspelund, A., Antila, S., Proulx, S. T., Karlsen, T. V., Karaman, S., Detmar, M., Wiig, H. et al., A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 2015. 212: 991–999.
128. Stern, J. N., Yaari, G., Vander Heiden, J. A., Church, G., Donahue, W. F., Hintzen, R. Q., Huttner, A. J. et al., B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Sci. Transl. Med. 2014. 6: 248ra107.
129. Alvermann, S., Hennig, C., Stuve, O., Wiendl, H. and Stangel, M., Immunophenotyping of cerebrospinal fluid cells in multiple sclerosis: in search of biomarkers. JAMA Neurol. 2014. 71: 905–912.